These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 35163599)

  • 61. Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?
    Voorrips SN; Saucedo-Orozco H; Sánchez-Aguilera PI; De Boer RA; Van der Meer P; Westenbrink BD
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955784
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Can we go beyond surrogates?
    Drexler A
    J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes.
    Woo VC
    Can J Diabetes; 2020 Feb; 44(1):61-67. PubMed ID: 31839265
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
    Packer M; Anker SD; Butler J; Filippatos G; Zannad F
    JAMA Cardiol; 2017 Sep; 2(9):1025-1029. PubMed ID: 28768320
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Treatment with sodium-glucose cotransporter-2 inhibitors in heart failure patients: The potential benefits of monitoring FGF-23 levels?
    Gruson D; Pouleur AC; Hermans MP; Ahn SA; Rousseau MF
    Ann Endocrinol (Paris); 2022 Feb; 83(1):78-80. PubMed ID: 34728212
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Commentary: Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Qiu M; Ding LL; Zhan ZL; Zhou HR
    Front Endocrinol (Lausanne); 2021; 12():664502. PubMed ID: 33841341
    [No Abstract]   [Full Text] [Related]  

  • 67. Impact of sodium-glucose co-transporter inhibitors on cardiac autonomic function and mortality: no time to die.
    Lim VG; He H; Lachlan T; Ng GA; Kyrou I; Randeva HS; Osman F
    Europace; 2022 Jul; 24(7):1052-1057. PubMed ID: 35080624
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects.
    Dyck JRB; Sossalla S; Hamdani N; Coronel R; Weber NC; Light PE; Zuurbier CJ
    J Mol Cell Cardiol; 2022 Jun; 167():17-31. PubMed ID: 35331696
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status.
    Matthews J; Herat L; Schlaich MP; Matthews V
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762542
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Cardioprotection by SGLT2 Inhibitors-Does It All Come Down to Na
    Trum M; Riechel J; Wagner S
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360742
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials.
    ;
    Lancet; 2022 Nov; 400(10365):1788-1801. PubMed ID: 36351458
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical efficacy of SGLT2 inhibitors with different SGLT1/SGLT2 selectivity in cardiovascular outcomes among patients with and without heart failure: A systematic review and meta-analysis of randomized trials.
    Lee MC; Hua YM; Yang CT; Kuo FH; Chang WT; Tang HJ; Siong Toh H; Lin YM; Chen SY; Chang HY; Liao CT
    Medicine (Baltimore); 2022 Dec; 101(51):e32489. PubMed ID: 36595871
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial.
    Lam CSP; Ramasundarahettige C; Branch KRH; Sattar N; Rosenstock J; Pratley R; Del Prato S; Lopes RD; Niemoeller E; Khurmi NS; Baek S; Gerstein HC
    Circulation; 2022 Feb; 145(8):565-574. PubMed ID: 34775781
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Storgaard H; Gluud LL; Bennett C; Grøndahl MF; Christensen MB; Knop FK; Vilsbøll T
    PLoS One; 2016; 11(11):e0166125. PubMed ID: 27835680
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatments for skeletal muscle abnormalities in heart failure: sodium-glucose transporter 2 and ketone bodies.
    Takada S; Sabe H; Kinugawa S
    Am J Physiol Heart Circ Physiol; 2022 Feb; 322(2):H117-H128. PubMed ID: 34860594
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value.
    Xie Y; Wei Y; Li D; Pu J; Ding H; Zhang X
    J Cardiovasc Pharmacol; 2023 Jan; 81(1):4-14. PubMed ID: 36607775
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks.
    Perry RJ; Shulman GI
    J Biol Chem; 2020 Oct; 295(42):14379-14390. PubMed ID: 32796035
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The Potential Roles of Osmotic and Nonosmotic Sodium Handling in Mediating the Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Heart Failure.
    Bjornstad P; Greasley PJ; Wheeler DC; Chertow GM; Langkilde AM; Heerspink HJL; Van Raalte DH
    J Card Fail; 2021 Dec; 27(12):1447-1455. PubMed ID: 34289398
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Sodium-glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients.
    Kashiwagi A; Araki S; Maegawa H
    J Diabetes Investig; 2021 Jan; 12(1):6-20. PubMed ID: 32563214
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Turning Foes to Friends: Knocking Down Diabetes Associated SGLT2 Transporters and Sustaining Life.
    Gupta A; Mittal S; Monika ; Dhingra R; Dhingra N
    Curr Diabetes Rev; 2020; 16(7):716-732. PubMed ID: 31951170
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.